1. Home
  2. TW vs BIIB Comparison

TW vs BIIB Comparison

Compare TW & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tradeweb Markets Inc.

TW

Tradeweb Markets Inc.

HOLD

Current Price

$106.05

Market Cap

22.9B

Sector

Finance

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$177.41

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TW
BIIB
Founded
1996
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.9B
24.2B
IPO Year
2019
1991

Fundamental Metrics

Financial Performance
Metric
TW
BIIB
Price
$106.05
$177.41
Analyst Decision
Buy
Buy
Analyst Count
12
22
Target Price
$140.83
$177.40
AVG Volume (30 Days)
1.1M
2.2M
Earning Date
02-05-2026
02-11-2026
Dividend Yield
0.45%
N/A
EPS Growth
40.82
N/A
EPS
2.93
10.97
Revenue
$1,992,479,000.00
$10,065,900,000.00
Revenue This Year
$22.50
$3.58
Revenue Next Year
$10.91
N/A
P/E Ratio
$36.25
$16.20
Revenue Growth
22.37
4.77
52 Week Low
$101.71
$110.04
52 Week High
$152.65
$185.17

Technical Indicators

Market Signals
Indicator
TW
BIIB
Relative Strength Index (RSI) 48.22 57.95
Support Level $103.08 $175.00
Resistance Level $108.82 $178.46
Average True Range (ATR) 1.90 3.50
MACD 0.26 -0.44
Stochastic Oscillator 60.10 86.16

Price Performance

Historical Comparison
TW
BIIB

About TW Tradeweb Markets Inc.

Founded in 1998 and headquartered in New York City, Tradeweb Markets is a leading fixed-income trading platform. While it does offer electronic processing for some voice-negotiated trades, the company focuses primarily on providing electronic trading networks that connect broker/dealers, institutional clients, and retail customers. While the company offers trading in a wide variety of products, the bulk of its business is in US and European government debt, mortgage-backed securities, interest-rate swaps, and US and international corporate bonds. The firm also sells fixed-income trading and price data, primarily through a deal with Refinitiv's Eikon service.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: